Barinthus Biotherapeutics plc. (BRNS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.74
- As of
Kresmion compiles this page from BRNS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Barinthus Biotherapeutics plc. (BRNS): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-09.
See the full BRNS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BRNS on one page. Preview it with sample data, then open it live with a free account.
Preview the BRNS dossierActive events for BRNS
- mediumEarnings above estimates
Q2-2026: Beat consensus by 9.0%, EPS $-0.26 vs $-0.2856 estimate
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 83% of BRNS (2026Q2)
- mediumEarnings below estimates
Q2-2025: Missed consensus by 54.5% - EPS $-0.52 vs $-0.3366 estimate
- mediumEarnings above estimates
Q3-2025: Beat consensus by 40.4% - EPS $-0.24 vs $-0.4029 estimate
- mediumEarnings above estimates
Q4-2025: Beat consensus by 23.3% - EPS $-0.27 vs $-0.3519 estimate
FREE, NO ACCOUNT
Every event on BRNS, as it fires
You are seeing 5 of 6 events recorded on BRNS since 2026-05-16.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BRNS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 91864C107 · 2026Q2 | $51K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 91864C107 · 2026Q2 | $17K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BRNS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BRNS against its peers
BRNS's return on equity of -89.5% ranks in the 53rd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-07-31.
| Metric | BRNS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 1.3M USD | 11 | 8 |
| Operating margin | n/a | -1403.3% | n/a | 7 |
| Net margin | n/a | -1106.7% | n/a | 7 |
| Return on equity | -89.5% | -93.9% | 53 | 15 |
Peers (16): AARD, GNTA, ALGS, BCTX, FLNA, RNAZ, MGX, IBO, ABVC, QNCX, CVM, LITS, CRVO, EYPT, EXOZ, IBIO. Left out: BSEM (no annual filing), RLFTY (no annual filing), MDNAF (no annual filing), CLCS (period gap), ZIVO (period gap), EVAX (no annual filing), SEOVF (no annual filing), TTIPF (no annual filing), IGC (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-07-31. Every figure is one full fiscal year read from one annual filing (BRNS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BRNS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BRNS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.